島松和正 (Kazumasa Shimamatsu, MD, PhD)

 

  1. Sanai T, Okamura K, Onoue T, Ono T, Motomura K, Miyazono M, Shimamatsu K. Hemodilution impacts assessment of thyroid status before and after hemodialysis in patients with end-stage renal disease. Am J Nephrol 2021; DOI 10.1159/000512968

2.  Shimamatsu, K. Long-term safety of a novel half-and-half (darbepoetin/epoetin) combination therapy in hemodialysis patients: a retrospective study. Rev de Educ 2020; 390(11):17-29 

3.   Koike K, Fukami K, Kawaguchi A, Shimamatsu K, Yamagishi S, Okuda S. Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodailysis patients. Int J Nephrol Renovasc Dis 9: 73-80, 2016

4.   Shimamatsu K. Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients. Clinicoecon Outcomes Res 6: 531-535, 2014

5.   Shimamatsu K, Inamasu H. A safe and easy introduction of darbepoetin-alpha in patients receiving maintenance hemodialysis and epoetin monotherapy: a “half-and-half” combination therapy. Curr Ther Res.74:5–8, 2013

6.   Shimamatsu K. Low-dose maintenance supplementation of intravenous iron chondroitin-sulfate colloid in hemodialysis patients. A 3-year follow-up. Dial Transplant 32: 595-598, 2003

7.   Shimamatsu K. Intermittent vs. continuous administration of 1α(OH)D3 on PTH suppression: Report of a case. Nephrol 8[Suppl]: A20-A21, 2003

8.   Shimamatsu K. Experience with i.v. iron chondroitin-sulphate colloid in Japanese haemodialysis patients. Nephrol Dial Transplant 13:1053, 1998

9.   Shimamatsu K. Diastolic blood pressure and progression of chronic renal failure. Nephron 55:436, 1990

10.   Sanai T., Okuda S., Onoyama K., Oochi N., Oh Y., Kobayashi K., Shimamatsu K., Fujimi S., Fujishima M. Germanium dioxide-induced nephropathy: A new type of renal disease. Nephron 54:53-60, 1990

11.    Onoyama K., Kumagai H., Takeda K., Shimamatsu K., Fujishima M. Effects of human recombinanat erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplnt 4:966-970, 1989

12.  Shimamatsu K., Onoyama K., Fujimi S., Iseki K., Fujishima M. Does 1α(OH)D3 treatment affect blood pressure levels in maintenance hemodialysis patients? Am J Nephrol 8:471-475, 1988

13.   Shimamatsu K., Nakamoto M., Inenaga T., Wada M., Fujimi S. Hemoperfusion-hemodialysis treatment for digoxin toxicity in a uremic patient. Cur Ther Res 43:27-31, 1988

14.   Motomura K., Okuda S., Sanai T., Hirakata H., Shimamatsu K., Onoyama K., Fujishima M. Aluminium hydroxide prevents progression in experimental focal glomerular sclerosis. Nephrol Dial Transplnt 3:263-268, 1988

15.   Shimamatsu K., Onoyama K., Fujimi S., Fujishima M. Parathyroid hormone suppression by 1 alpha-hydroxycholecalciferol in chronic hemodialysis patients. Cur Ther Res 41:374-379, 1987

16.   Shimamatsu K., Fujimi S., Onoyama K., Tsuruda H., Fhijishima M. Residual renal function with different frequencies of hemodialysis treatment in end-stage renal failure patients. J Jpn Soc Dial Ther 20:105-109, 1987

17.   Okuda S., Kiyama S., Oh Y., Shimamatsu K., Oochi N., Kobayashi K., Nanishi F., Fujimi S., Onoyama K., Fujishima M. Persistent renal dysfunction induced by chronic intake of germanium-containing compounds. Cur Ther Res 41:265-275, 1987

18.   Kumagai H., Inenaga T., Shimamatsu K., Nakamoto M., Fujimi S., Harada a., Onoyama K. A case of acute poststreptococcal glomerulonephritis associated with cerebral hemorrhage. Jpn J Nephrol 29:1175-1179, 1987

19.   Kumagai H., Onoyama K., Hirakata H., Katafuchi R., Hori K., Oochi N., Tsuruda H., Inenaga T., Okuda S., Nanishi F., Shimamatsu K., Fujimi S., Fujishima M. Bradyarrhythmia induced by orally administered verapamil and propranolol in chronic hemodialysis patients. Cur Ther Res 40:1-6, 1986

20.   Shimamatsu K., Fouad-Tarazi FM. Basal inotropic state in rats with renal hypertension: Influence of coronary flow and perfusion pressure. Cardiovasc Res 20:269-274, 1986

21.   Fouad FM., Shimamatsu K., Said SI., Tarazi RC. Inotropic responsiveness in hypertensive left ventricular hypertrophy: Impaired inotropic response to glucagons and vasoactive intestinal peptide in renal hypertensive rats. J Cardiovasc Pharmacol 8:398-405, 1986

22.   Shimamatsu K., Onoyama K., Harada H., Kumagai H., Hirakata H., Miishima C., Inenaga T., Fujimi S., Fujishima M., Omae T. Effect of blood pressure on the progression rate of renal impairment in chronic glomerulonephritis. J Clin Hypertens 3:239-244, 1985

23.   Fouad FM., Shimamatsu K., Hanna MM., Khairallah PA., Tarazi RC. Impaired inotropic responses toα-adrenergic stimulation in experimental left ventricular hypertrophy. Circulation 71:1023-1028, 1985

24.   Shimamatsu K., Onoyama K., Maeda T., Ohryoji F., Fujimi s., Omae T. Massive pulmonary embolism occurring with corticosteroid and diutetics therapy in a minimal-change nephritic patient. Nephron 32:78-79, 1982

25.   Shimamatsu K., Maeda T., Harada A., Nishitani H., Onoyama K., Fujimi S., Omae T. 1-year controlled trial of 1α-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 28:70-75, 1981

26.   Kobayashi K., Harada A., Onoyama K., Shimamatsu K., Maeda T., Fujimi S., Omae T. Idiopathic membranous glomerulonephritis associated with diabetes mellitus. Nephron 28:163-168, 1981 

27.   Iseki K., Onoyama K., Maeda T., Shimamatsu K., Harada A., Fujimi S., Omae T. Comparison of hemodynamics induced by conventional acetate hemodialysis, bicarbonate hemodialysis and ultrafiltration. Clin Nephrol 14:294-298, 1980